Showing 9081-9090 of 21418 results for "".
Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
https://reachmd.com/programs/cme/future-proofing-in-hae-advances-in-long-term-prophylaxis-to-prevent-attacks-and-improve-quality-of-life/54448/On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
https://reachmd.com/programs/heart-matters/early-initiation-of-acoramidis-in-attr-cm-importance-and-long-term-impacts/35757/Acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), was studied in an open-label extension of the ATTRibute-CM trial to determine whether its early and sustained use improves clinical outcomes. Discover acoramidis’ long-term impacts on all-cause mortality and/or first cardiovTreating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
https://reachmd.com/programs/project-oncology/treating-rr-classic-hodgkin-lymphoma-ipilimumab-and-other-approaches/26405/Read about the efficacy and safety of ipilimumab as a standalone treatment for relapsed or refractory classic Hodgkin lymphoma.Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
https://reachmd.com/programs/cme/employing-immunotherapy-and-adcs-in-advanced-endometrial-and-cervical-cancers-current-and-emerging-therapies/14460/Our experts are breaking down evolving treatments for advanced endometrial & cervical cancer. Hear the latest data on immunotherapy and ADCs now!Investigating the Circulation of Counterfeit COVID-19 Medications
https://reachmd.com/programs/covid-19-frontlines/investigating-the-circulation-of-counterfeit-covid-19-medications/11624/The worldwide shortfall of drugs and drug supplies has fueled an illicit trade market for illegal pharmaceuticals and medical items.Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19
https://reachmd.com/programs/the-drug-report/renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-covid-19/11416/Do the benefits of continuing the use of RAAS inhibitors in patients outweigh the risks due to the inhibitors’ potential link to COVID-19 severity?Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
https://reachmd.com/programs/cme/improving-quality-care-across-the-spectrum-of-her2-expression-in-hr-metastatic-breast-cancers-practice-changes-to-improve-care/32203/This panel discussion reviews successes, challenges, and practice insights from a Quality Improvement (QI) initiative in metastatic breast cancer.A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
https://reachmd.com/programs/cme/a-new-paradigm-in-igan-managementadvancing-clinical-practice-in-the-era-of-therapeutic-expansion/54415/On-demand webcast on the latest advances in diagnosing and managing patients with IgA nephropathy (IgAN), including the current data on new and emerging IgAN therapies.A Case-Based Discussion on Managing Adult Patients With C3G or IC-MPGN in the Era of Complement Inhibition
https://reachmd.com/programs/cme/a-case-based-discussion-on-managing-adult-patients-with-c3g-or-ic-mpgn-in-the-era-of-complement-inhibition/54144/Examine case-based treatment optimization for adults with C3G or primary IC-MPGN, including the use of complement-targeted therapies.Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/54306/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.